Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/live-biotherapeutic-product-manufacturing-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Live Biotherapeutic Product ManufacturingLive biotherapeutic product manufacturing patents: mapping who owns strain banking, fermentation and stability claims
- 47.3% concentration. The five leading assignees hold 204 of 431 records in scope — filing here is unusually concentrated for a manufacturing-process field.
- Filings have fallen sharply since the 2020 peak. From 29 records in 2020, activity dropped to 10 in 2021 and 1 in 2024 (-90% over that span) — the last complete filing years, before publication lag affects 2025-2026.
- C12N and C12P dominate the claim space. 70.8% and 56.1% of records respectively sit in microorganism/genetic-engineering and fermentation classes, leaving stability and testing classes comparatively open.
431
Published Records
47%
Top-5 Share of All Records
-90%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (10 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 431 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview
What this landscape covers
Live biotherapeutic product manufacturing sits at the intersection of strain handling and process engineering: anaerobic fermentation, strain banking, oxygen-sensitivity control, viable count assays, lyophilization survival and batch consistency testing. This search combines those manufacturing-process terms with the core live biotherapeutic and fermentation vocabulary, capturing 431 published records between 2015 and mid-2026.
The records skew toward upstream microbial engineering and fermentation chemistry rather than downstream formulation and QC, which shows up clearly in the IPC composition below. Publication lags filing by roughly 18 months, so figures for 2025 and 2026 are still incomplete and should be read as a floor, not a ceiling.
Filing activity and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Data
Filing trend and technology composition
Two views of the same 431 records: how filing activity moved year over year, and which IPC subclasses the claims actually sit in.
A sharp drop from a 2020 peak
Filings rose to a peak of 29 records in 2020, then fell to 10 by 2021 and to 1 by 2024 — a decline of 90% over that three-year window, the last stretch of years complete enough to compare. Treat 2025 and 2026 counts as understated until later publications catch up.
Fermentation and microorganism classes dominate
C12N (microorganisms & genetic engineering) appears in 70.8% of the 431 records and C12P (fermentation & enzymatic synthesis) in 56.1%, confirming that most claims are anchored in strain construction and fermentation process steps. A61K (medicinal preparations) at 23.0% and G01N (material analysis & testing) at 8.8% mark the smaller, less-crowded downstream territory around formulation and quality testing.
Shares are the percentage of the 431 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Live Biotherapeutic Product Manufacturing with Eureka
This page is one run against one query. Ask Eureka your own question about live biotherapeutic product manufacturing and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Representative filing and most-cited prior art
Representative Record
US20210164001A1 — Capturing and converting CO2 into biodegradable bioplastic
KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
A two-stage fermentation process converts a CO2/H2 gaseous substrate into polyhydroxyalkanoate (PHA) bioplastic: an anaerobic stage using an acetogenic microorganism produces an acid-containing culture medium, followed by an aerobic stage using a PHA-producing microorganism.Filed by King Abdullah University of Science and Technology, published 2021-06-03.
Most-cited records in this landscape
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2014167338A1 | Roseburia flagellin and immune modulation | 209 |
| 2 | WO2009094485A1 | Methods and organisms for utilizing synthesis gas or other gaseous carbon sources and methanol | 182 |
| 3 | US20150071957A1 | Polypeptide and immune modulation | 165 |
| 4 | US20030211585A1 | Methods for increasing the production of ethanol from microbial fermentation | 161 |
| 5 | US20090155869A1 | Engineered microorganisms for producing n-butanol and related methods | 113 |
| 6 | US20090191593A1 | Methods and organisms for utilizing synthesis gas or other gaseous carbon sources and methanol | 102 |
| 7 | US7256016B2 | Recycling system for manipulation of intracellular NADH availability | 89 |
| 8 | JP1990283289A | Preparing and purifying process for succinic acid | 75 |
| 9 | US9796762B2 | Polypeptide and immune modulation | 66 |
| 10 | US20100227377A1 | Method for sustaining Microorganism culture in Syngas fermentation process in decreased concentration or abse… | 66 |
Citation counts inside a searched corpus favour older filings — read them as a signal of influence within the field, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for filing strategy
Three patterns stand out once the records are grouped by assignee, year and IPC class.
Concentration
47.3%
of 431 records held by top 5 assignees
The field is unusually concentrated for a process technology
Top 5 assignees combined account for 204 of 431 records (47.3%), and the top 10 hold 310 (71.9%). That is a steep concentration curve for a manufacturing-process area, where process variations usually spread claims across many smaller filers.
Denominator: all 431 records in scope
Momentum
-90%
filings 2021 to 2024
Recent-year activity has gone quiet across the leaders
Filing fell from 10 records in 2021 to 1 in 2024, a 90% drop over the last three complete filing years. Recent-year momentum tracking shows several of the largest historical assignees recording zero filings in the latest year, consistent with the broader slowdown rather than an isolated retreat.
2021-2024 span; 2025-2026 undercounted by publication lag
Composition
8.8%
of records in G01N testing class
Testing and QC claims remain a minority share
Only 38 of 431 records (8.8%) fall in G01N material analysis & testing, and just 29 (6.7%) sit in C12R microorganism indexing — both far behind the 70.8% share held by core C12N microorganism engineering. Viable count assay and strain identity confirmation methods, central to the search terms, appear thinly represented relative to upstream strain and fermentation work.
Denominator: all 431 records; classes overlap so shares exceed 100%
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to live biotherapeutic product manufacturing, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who holds the ground, and where filing has stopped
The assignee ranking returns 100 companies across the full dataset — not a curated top-50 or top-100 list, but the complete set the search endpoint surfaces.
Leader
75
records for the top-ranked assignee
One filer holds a lead well ahead of the field
The leading assignee holds 75 records, compared with 26 at fifth place and 18 at tenth. The gap between first and fifth is wide enough that a new entrant cannot expect to compete on volume alone in the core fermentation and strain-construction classes.
Ranking denominator: 431 records
Long tail
121
records outside the top 10 (431 minus 310)
A long tail sits behind the top 10
The top 10 assignees combined hold 310 of 431 records (71.9%), leaving the remaining 121 records spread across the other 90 ranked companies. That tail includes university research foundations and single-strain biotech filers rather than large industrial players.
Top 10 vs. remainder of 431 records
Co-filing
13
co-assigned records, strongest pair
Co-assignments cluster around a handful of research partnerships
Only 10 co-assignee pairs appear in the dataset, and the strongest links a university research foundation with a diagnostics company at 13 shared records. Co-filing is not the norm here; most records carry a single assignee.
10 co-assignee pairs identified across 431 records
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Allergan Inc | 0 | — |
| 4D Pharma Research Ltd | 0 | — |
| Gevo Inc | 0 | — |
| Ineos Bio SA | 0 | — |
| LanzaTech NZ Inc | 0 | — |
| ENTEROBIOME INC | 0 | — |
| Genomatica Inc | 0 | — |
| University of Georgia Research Foundation Inc | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this next
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, sourcing, or identifying open claim space.
Check freedom-to-operate against the concentrated leaders
With 47.3% of records held by five assignees, any new fermentation or strain-banking filing should be checked against the leading assignees' claim scope before drafting.
Run a freedom-to-operate check in EurekaInvestigate the testing and QC white space
G01N and C12R classes remain thin relative to core fermentation claims, suggesting viable count assay and batch consistency methods are less crowded than strain-construction claims.
Explore white space in EurekaWatch for renewed filing as the slowdown may reverse
The 2021-2024 drop coincides with the window most affected by publication lag; 2025-2026 filings are still incomplete and could change the trend once fully published.
Track filing trends in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
One assignee leads with 75 of the 431 records in scope, well ahead of the fifth-ranked assignee at 26 and the tenth-ranked at 18. The top 5 assignees combined hold 204 records, or 47.3% of the total, which is a high concentration for a manufacturing-process field. That said, the ranking covers 100 companies in total, so a long tail of smaller filers, including university research foundations, still accounts for a meaningful share of activity.
No — filing peaked at 29 records in 2020 and has fallen sharply since, dropping from 10 records in 2021 to just 1 in 2024, a decline of 90% over that span. Those are the last years complete enough to compare reliably; 2025 and 2026 figures are still filling in because publication typically lags filing by around 18 months. The honest read is that visible filing activity has cooled substantially through 2024, not that the technology itself has stalled.
C12N, covering microorganisms and genetic engineering, appears in 70.8% of the 431 records, and C12P, covering fermentation and enzymatic synthesis, appears in 56.1%. Together they show that most patent activity centres on strain construction and fermentation process steps rather than downstream formulation. Smaller shares fall in A61K medicinal preparations (23.0%) and G01N material analysis and testing (8.8%), marking the less-crowded parts of the manufacturing pipeline.
The testing and quality-control side of the pipeline is comparatively under-claimed: G01N material analysis and testing sits at just 8.8% of the 431 records, and C12R microorganism indexing at 6.7%, both far below the 70.8% held by core microorganism engineering claims. Specific candidates include viable count assay standardisation, strain identity confirmation methods, and lyophilization survival optimisation — all named in the underlying search terms but thin in the claim record relative to fermentation and strain-construction work.
The United States receives the most filings in this dataset at 133 records, followed by the European Patent Office at 55, Canada at 34, the WIPO PCT route at 29, India at 22, and Australia at 18. This spread suggests filers are pursuing broad multi-jurisdiction protection through PCT alongside direct US and European filings, which is typical for biotherapeutic manufacturing processes intended for global commercialisation.
Answers are grounded in the same dataset. Derived from a Patsnap search on Live Biotherapeutic Product Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Live Biotherapeutic Product Manufacturing in depth with Eureka
Go past this page: query the whole live biotherapeutic product manufacturing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.